Successful combined surgical and octreotide treatment of severe pretibial myxoedema reviewed after 9 years [3]

British Journal of Dermatology

Volumn 148, Issue 4, 2003, Pages 825-826

  Felton, J ^a   Derrick, E K ^a   Price, M L ^a  

^a BRIGHTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; THYROXINE;

ADULT; CASE REPORT; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; LETTER; MALE; MYXEDEMA; OPHTHALMOPLEGIA; PRIORITY JOURNAL; SUBTOTAL THYROIDECTOMY; THYROTOXICOSIS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEG DERMATOSES; MALE; MIDDLE AGED; MYXEDEMA; OCTREOTIDE;

EID: 0038578749     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05236.x     Document Type: Letter

References (6)

1. Derrick EK, Tanner B, Price ML. Successful surgical treatment of severe pretibial myxoedema. Br J Dermatol 1995; 133: 317-18.
2. Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 2002; 87: 438-46.
3. Gunasekera CN, Ostlere LS, Mortimer PS. Surgery for pretibial myxoedema. Br J Dermatol 1996; 135: 155 (Letter).
4. Shinohara M, Hamasaki Y, Katayama I. Refractory pretibial myxoedema with response to intralesional insulin-like growth factor 1 antagonist (octreotide): downregulation of hyaluronic acid production by the lesional fibroblasts. Br J Dermatol 2000; 143: 1083-6.
5. Chang TC, Kao SC, Huang KM. Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Br Med J 1992; 304: 158.
6. Priestley GC, Aldridge RD, Sime PJ, Wilson D. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin) in vitro. Br J Dermatol 1994; 131: 52-6.